Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders where several key proposals were approved. Shareholders elected three Class II directors and ratified CBIZ CPAs P.C. as the independent auditor. Crucially, stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing available shares to 402,214. Additionally, proposals for the issuance of shares underlying certain warrants and the repricing of warrants for up to 120,734 shares were also approved, along with an adjournment proposal.

Dermata Therapeutics reported a net loss of $(1.85) million for Q1 2026, an improvement from $(2.30) million in Q1 2025. However, the company's cash and cash equivalents decreased to $6.9 million, and management expressed substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into Q1 2027. The company is shifting focus to direct-to-consumer skincare products, with the first launch anticipated in mid-2026.

Dermata Therapeutics announced its new direct-to-consumer (DTC) skincare brand, Tome, and plans to launch its first product, the Tome Foundational Treatment, a once-weekly mask, in mid-2026. The company also reported a net loss of $1.8 million for Q1 2026, an improvement from $2.3 million in Q1 2025. Dermata raised $2.0 million in net proceeds from its at-the-market (ATM) financing facility, which is expected to fund operations into Q1 2027.